Please login to the form below

Not currently logged in
Email:
Password:

Novartis releases trial results backing Gilenya safety profile

Data comes just days after a patient died after starting on the MS treatment

Novartis says new late-stage trial results for Gilenya (fingolimod) confirm the safety record of its oral multiple sclerosis drug.

Earlier this week the pharma company said it was investigating whether the drug was linked to the death of a patient who died shortly after starting on Gilenya.

Novartis previously said the role of Gilenya in the patient's death, which occurred within 24 hours of first taking the drug on November 23, could neither be excluded or confirmed.

The company said the new phase III trial results for Gilenya indicated its safety and tolerability was consistent with earlier studies.

Adverse events documented among Gilenya users in the trial included elevations of liver transaminase, hypertension and low levels of lymphocytes. Incidents of more serious events, such as systematic low heart rate and associated atrioventricular blockages, were rare and no deaths were recorded.

The trial, called Study 2309, was mainly performed to provide further safety data required by Gilenya's US approval last year.

The two-year placebo-controlled, parallel-group, multi-center phase III clinical trial  involved 1,083 patients across 126 sites in eight countries with most of patients enrolled in the US.

Novartis said study 2309 suggested that use of Gilenya, an oral treatment for relapsing-remitting multiple sclerosis (RRMS), showed a significant reduction in annualised relapse rate, meeting its primary endpoint.

RRMS patients treated with the drug had a 48 per cent reduction in annualised relapse rates (ARR) at 24 months compared to placebo. These results also backed up two previous trials, which showed reductions in relapse rates for patients on Gilenya compared to both placebo and Merck Serono's Rebif (interferon beta-1a).

Brain volume loss, a predictor of long-term disability, was also shown to achieve significant reduction in Gilenya patients compared to placebo.

David Epstein, head of Novartis' Pharmaceuticals Division said: "Study 2309 confirms the efficacy of Gilenya across several key measures, including reductions in annualised relapse rate and reductions in brain volume loss.

"With more than 20,000 patient years of fingolimod exposure to date, Gilenya continues to demonstrate its value to patients and the MS community. We are looking forward to presenting the full data to the clinical community at a scientific congress next year."

Gilenya is the first drug of its class approved in the EU and the US, but has yet to be accepted by the National Institute for Health and Clinical Excellence (NICE) for use on the NHS in England and Wales.

NICE's second draft guidance on Gilenya said that, even with a patient access scheme proposed by Novartis, the benefits of the drug were not worth its expense.

16th December 2011

Share

PMEA Awards 2020

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Aurora Healthcare Communications

We're a leading healthcare strategic communications agency helping pharmaceutical companies adapt fast to improve the lives of patients and healthcare...

Latest intelligence

What’s in it for me? How to engage, motivate and support staff with internal training at OPEN Health
...
Environmental impact of in-person vs. virtual meetings
Although it will be tempting to resume in-person activities in the same capacity as before, we need to weigh the pros and cons of virtual vs. in-person vs. hybrid events...
US biosimilars
The US celebrates five years of biosimilars on the market – a look to the past, present and future
Why the success of biosimilars in the US has been mixed...

Infographics